The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Hepatitis B Virus (HBV) peptides.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Hepatitis B Virus (HBV) peptides is a key innovation area in pharmaceutical
HBV peptides represent peptides derived from the hepatitis B virus (HBV). These may serve as HLA class I-restricted T cell epitopes and can be used as an antigen-specific positive control to stimulate T cells. Vaccination with these peptides is a promising new treatment strategy for chronic HBV.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of Hepatitis B Virus (HBV) peptides.
Key players in Hepatitis B Virus (HBV) peptides – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Globeimmune is the leading patent filer in Hepatitis B Virus (HBV) peptides. It is focused on the treatment of cancer and infectious diseases based on proprietary Tarmogen platform. Tarmogens activate a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominately stimulate antibody production.
In terms of application diversity, Proteome Sciences is the top company, followed by Biogen and Chimeros. By means of geographic reach, Celltrion holds the top position, while Biomay and Catalent stand in the second and third positions, respectively. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
#leading #innovators #Hepatitis #Virus #HBV #peptides #pharmaceutical #industry